Mary Ellen Hackett
Manager, Communications Office
Email maryellen.hackett@nih.gov or call 301-401-8670 for all media related questions.
Featured News
All News
Exosomes in personalized medicine for pancreatic cancer
Nature’s own delivery system meets precision oncology: the decade-long journey of engineered exosomes to a first-in-human KRAS trial.POSTED: 1/12/2026
LZTR1: How it recognizes, binds, and degrades RAS proteins
New structures reveal how LZTR1 recognizes inactive RAS proteins for degradation, opening a new path to therapeutically eliminate oncogenic KRAS.POSTED: 12/15/2025
Unpacking the diversity among KRAS mutants
From KRAS G12D to KRAS G12R, new research uncovers how each mutation drives pancreatic cancer differently—and why it matters for patient outcomes.POSTED: 11/19/2025
The allele-specific lipid sensing of KRAS mutants
KRAS mutants don’t just anchor to membranes—they choose their lipid partners. Discover how this specificity could unlock new cancer therapies.POSTED: 7/8/2025
Therapeutic strategies to overcome KRAS (OFF) inhibitors resistance
Understanding and overcoming resistance to KRAS G12C inhibitors remains a key focus in the fight against RAS-driven cancers. Experts describe non-genetic methods of resistance to G12C inhibitors that bind to the inactive, GDP-bound form of the protein, and propose the best therapeutic strategy.POSTED: 9/26/2024
MAP2K4: New kid on the MAP Kinase block
Post-doc Robin A Jansen and her advisor Rene Bernards lay out a compelling argument for MAP2K4 inhibition as an effective combination therapy with RAS-targeted drugs.POSTED: 6/18/2024
AI-generated protein biosensors enable quantitative measurements of endogenous RAS activity in live cells
Measuring active RAS levels in live cells has long been a challenge—until now. Discover how AI-designed biosensors reveal where and how Ras signals inside cells, reshaping cancer research.POSTED: 4/30/2024
Top-Down Proteomics Reveals the KRAS Proteoform Landscape in Colorectal Cancer
Learn about how top-down proteomics uncovered novel KRAS proteoforms, and how this gives us a better understanding of colorectal cancer.POSTED: 3/24/2024
Development of Mutant KRAS Molecuar Target Drugs and Future Prospects: Report
Drs. Fuyuhiko Tamanoi, Hideyuki Saya, Toshio Imai, and Kiyoko Kato present a report of the online meeting that they organized, titled “Development of mutant KRAS molecular target drugs and future prospects.”POSTED: 2/29/2024